Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
5 pending office actions • 4 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days
Dna Script is managing 5 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are spread across 5 distinct examiners and 4 distinct art units. This distribution indicates a relatively broad prosecution effort, with the company's biotechnology filings reaching multiple specialized groups within the patent office.
HOPE A ROBINSON is the busiest examiner for the company, with 1 pending office action. The distribution of pending actions among the distinct examiners shows that no single examiner is handling more than a single action for this portfolio. This wide allocation across 4 distinct art units suggests that Dna Script is pursuing a variety of technical innovations that fall under different examination specialties. For practitioners, this means the company must manage multiple examiner relationships and varying art unit standards simultaneously.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (20%) |
| Double-patenting + other | 1 (20%) |
| Multi-statute (no §101) | 3 (60%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ROBINSON, HOPE A | 1 | 67.7% | +43.1% |
| ZAHORIK, AMANDA MARY | 1 | 57.8% | +49.0% |
| SU-TOBON, QIWEN NMN | 1 | 66.7% | +66.7% |
| YU, DELPHINUS DOU YI | 1 | 33.3% | +0.0% |
| YAMASAKI, ROBERT J | 1 | 67.6% | +43.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17629322 | Increasing Long-Sequence Yields In Template-Free Enzymatic Synthesis of Polynucleotides | YAMASAKI, ROBERT J | 27d |
| 18709292 | NOVEL TERMINAL DEOXYNUCLEOTIDYL TRANSFERASE (TdT) VARIANT AND USES THEREOF | ROBINSON, HOPE A | — |
| 18686319 | METHOD FOR GENERATING DOUBLE-STRANDED NUCLEIC ACID | ZAHORIK, AMANDA MARY | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17629322 | Increasing Long-Sequence Yields In Template-Free Enzymatic Synthesis of Polynucleotides | YAMASAKI, ROBERT J | 27d |
| 18709292 | NOVEL TERMINAL DEOXYNUCLEOTIDYL TRANSFERASE (TdT) VARIANT AND USES THEREOF | ROBINSON, HOPE A | — |
| 18686319 | METHOD FOR GENERATING DOUBLE-STRANDED NUCLEIC ACID | ZAHORIK, AMANDA MARY | — |
| 18027594 | Stabilized N-Terminally Truncated Terminal Deoxynucleotidyl Transferase Variants and Uses Thereof | SU-TOBON, QIWEN NMN | — |
| Art Unit | Apps |
|---|---|
| 1652 | 1 |
| 1636 | 1 |
| 1656 | 1 |
| 1657 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18709292 | NOVEL TERMINAL DEOXYNUCLEOTIDYL TRANSFERASE (TdT) VARIANT AND USES THEREOF | ROBINSON, HOPE A | 1652 | §103§112 | Final Rejection | — | Pending | May 10, 2024 |
| 18686319 | METHOD FOR GENERATING DOUBLE-STRANDED NUCLEIC ACID | ZAHORIK, AMANDA MARY | — | §102§103§112 | Non-Final OA | — | Pending | Feb 23, 2024 |
| 18027594 | Stabilized N-Terminally Truncated Terminal Deoxynucleotidyl Transferase Variants and Uses Thereof | SU-TOBON, QIWEN NMN | 1636 | §103§112DP | Non-Final OA | — | Pending | Aug 21, 2023 |
| 18034487 | Enzymatic Synthesis of Polynucleotide Probes | YU, DELPHINUS DOU YI | 1656 | §112 | Non-Final OA | — | Pending | Apr 28, 2023 |
| 17629322 | Increasing Long-Sequence Yields In Template-Free Enzymatic Synthesis of Polynucleotides | YAMASAKI, ROBERT J | 1657 | §103§112 | Non-Final OA | 27d | Pending | Jan 21, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial